373 related articles for article (PubMed ID: 17764565)
1. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
2. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
Feng W; Orlandi R; Zhao N; Carcangiu ML; Tagliabue E; Xu J; Bast RC; Yu Y
BMC Cancer; 2010 Jul; 10():378. PubMed ID: 20642860
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
[TBL] [Abstract][Full Text] [Related]
5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
6. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
7. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
9. [Methylation status and protein expression of adenomatous polyposis coli (APC) gene in breast cancer].
Liu Z; Yang L; Cui DX; Liu BL; Zhang XB; Ma WF; Zhang Q
Ai Zheng; 2007 Jun; 26(6):586-90. PubMed ID: 17562262
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
[TBL] [Abstract][Full Text] [Related]
12. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
Jing F; Yuping W; Yong C; Jie L; Jun L; Xuanbing T; Lihua H
Tumour Biol; 2010 Aug; 31(4):321-31. PubMed ID: 20490964
[TBL] [Abstract][Full Text] [Related]
13. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
18. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
19. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
